Nautilus
Nautilus is introducing the first large-scale, single-molecule platform designed to comprehensively quantify the proteome.
Challenge
How do you publicly debut the company driving the proteomic revolution to enable fundamental advancements in human health?
Challenge
Nautilus Biotechnology is developing a platform with the potential to democratize access to the proteome and enable fundamental advancements across human health and medicine.
In June 2021, Nautilus was preparing to debut as a publicly traded company via a special purpose acquisition company (SPAC) merger and announce its advanced proteomics platform.
In advance of the unveiling, we partnered with the company to amplify public awareness of its team, technology, and the promise of proteomics to revolutionize diagnostics, therapeutics, and basic science research.
Our scope was to support strategic communications around the company’s corporate milestones including its public listing on Nasdaq via SPAC; partnerships with Abcam, Amgen, and MD Anderson Cancer Center; and key appointments to its executive team and scientific advisory board.
To share with the world the potential of proteomics to offer insight and opportunity beyond what genomics has provided, we deployed media and thought leadership campaigns; drove social media content and technical white paper creation; and clarified positioning and messaging to promote mainstream understanding of proteomics and Nautilus’ approach:
- The impact that accelerating our understanding of the proteins in our bodies can have on improving human health
- The platform designed to radically improve upon existing protein analysis tools measuring the industry standard of 8% of the proteome to more than 95%
- The company’s unmatched ability to deliver on the untapped potential of the human proteome and drive the new proteomic era with industry and academic partners
- The founders Sujal Patel and Parag Mallick and their growing executive team’s interdisciplinary experience across computer science, engineering, biochemistry, and as part of the genomic revolution to bring the sensitivity, scale, and power of DNA sequencing to the field of proteomics
Impact
The media coverage of Nautilus’ public debut engaged more than 238 million online viewers on a mix of broadcast, business, and trade platforms, rising to 489 million by the end of 2021 as a result of our milestone and thought leadership campaigns.
Bloomberg Television hosted Nautilus CEO Sujal Patel on its live broadcast show “Bloomberg Technology” to discuss the company’s role in accelerating drug development through proteomics.
Additional tier 1 business outlets including Forbes and The Seattle Times featured the company’s journey, from its founding to unlock the diversity and complexity of the human proteome as a rising startup to successfully listing as a public company to advance and commercialize its platform.
Led by proteomics expert and Chief Scientist Parag Mallick, Nautilus’ position as the team pioneering the first large-scale, single-molecule platform designed to comprehensively quantify the proteome has received industry recognition from the BioTech Breakthrough Awards and continues to be highlighted in key trade outlets such as GeekWire, GenomeWeb, and Bio-IT World. Chemical and Engineering News’ cover story examining the “dark proteome” featured Nautilus as the company developing the breakthrough technology for uncovering unknown proteins.
Founders Mallick and Patel have established national platforms reaching biopharma, academic, and public audiences through their appearances at the Tough Tech Summit and on the a16z Bio Live program, the Genetic Engineering and Biotechnology News “Close to the Edge” series, SynBioBeta’s “Built With Biology” show, and Human Proteome Organization (HUPO) webinars.
As Nautilus’ executive team and board expanded, their unique expertise as scientific pioneers and entrepreneurs was covered by publications including STAT News, FierceBiotech, Endpoints News, BioSpace, and San Diego Business Journal.
Our framework of communication, media, content, and business and scientific thought leadership strategies continues to drive cognizance of Nautilus’ vision, team, and technology as they expand and come to fruition to revolutionize biomedicine.
“We have reimagined how to comprehensively analyze and quantify the proteome. In doing so, we are seeking to create a new gold standard in the field of proteomics that will lead to positive impacts on human health. We believe our technology will change the scale of what is possible in proteomics in an effort to enable significant advancements in drug development and help revolutionize the way biomedical research is conducted.”
Sujal Patel – Co-founder and CEO, Nautilus Biotechnology
IPO
SPAC announced
3
partnerships announced
489+MM
